Fox Run Management’s BridgeBio Pharma BBIO Stock Holding History

Fox Run Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,053	Closed	-$212K	–	937
2026 Q1	$212K	Sell	3,053 -10,670	-78%	-$773K	0.04%	749
2025 Q4	$1.05M	Buy	13,723 +776	+6%	+$50.9K	0.16%	193
2025 Q3	$672K	Sell	12,947 -50,657	-80%	-$2.47M	0.1%	375
2025 Q2	$2.75M	Buy	+63,604	New	+$2.31M	0.46%	6
2023 Q2	–	Sell	-24,551	Closed	-$407K	–	692
2023 Q1	$407K	Sell	24,551 -7,636	-24%	-$89K	0.13%	289
2022 Q4	$245K	Buy	+32,187	New	+$308K	0.1%	415

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fox Run Management's BBIO Position: Q2 2026 in Review

Fox Run Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 3,053 shares — an estimated $212K sold.

Fox Run Management first reported a position in BBIO in Q4 2022 and held it in 6 quarters. The position peaked at $2.75M in Q2 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Fox Run Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 3,053 BridgeBio Pharma shares in Q2 2026, an estimated $212K.
Fox Run Management first reported a position in BridgeBio Pharma in Q4 2022 and held it in 6 quarters.
Fox Run Management's BridgeBio Pharma position peaked at $2.75M in Q2 2025.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.